Original Article

Performance and clinical comparison between left ventricular quadrupolar and bipolar leads in cardiac resynchronization therapy: Observational research

M. Ziacchi1,*, G. Zucchelli2, D. Ricciardi3, G. Morani4, E. De Ruvo5, V. Calzolari3, S. Viani6, V. Calabrese5, L. Tomasi4, L. Calò6, L. De Mattia1, M.G. Bongiorni1, G. Boriani2,3,4,5,6,8, M. Biffi3

1 Istituto di Cardiologia, Policlinico S. Orsola-Malpighi, Università di Bologna, Bologna, Italy
2 Cardiologia, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
3 Cardiologia, Policlinico Universitario Campus Biomedico, Roma, Italy
4 Cardiologia, Azienda Ospedaliera Universitaria di Verona, Verona, Italy
5 Cardiologia, Policlinico Ospedaliero M. Bufalini, Cesena, Italy
6 Dipartimento di Cardiologia, Università di Modena e Reggio Emilia, Modena, Italy

ARTICLE INFO

Article history:
Received 19 July 2017
Accepted 6 May 2018
Available online 16 May 2018

Keywords:
Short-spaced quadrupolar lead
Cardiac resynchronization therapy
Phrenic nerve stimulation
Heart failure
Re-implantation

ABSTRACT

Aim: To evaluate Attain Performa (Medtronic, Dublin, Ireland) quadrupolar lead performance in clinical practice and, secondarily, to compare its long-term clinical outcomes vs bipolar leads for left ventricular (LV) pacing.

Methods and results: We retrospectively analyzed clinical, procedural and follow-up data of 215 patients implanted with a quadrupolar lead. One hundred and twenty-one patients implanted with bipolar lead were selected to compare long-term clinical outcomes. The quadrupolar lead was implanted in the target vein in 196 patients (91%) without acute dislodgements. In 50% of patients the chosen final pacing configuration at implant would not have been available with bipolar leads. A dedicated quadrupolar pacing vector was chosen more frequently when the LV tip location was apical than otherwise (65.6% vs 42.7%, p = 0.003). After a median follow-up of 14 months, the LV pacing threshold was less than 2.5 V at 0.4 ms in 98 patients (90%) with a safety margin between phrenic nerve and LV pacing threshold >3 V in 97 patients (89%). We observed a slight trend towards a lower risk of heart failure worsening and a lower incidence of ventricular arrhythmias and pulmonary congestion in patients implanted with quadrupolar leads compared with the control group.

Conclusion: Quadrupolar leads improve the management of phrenic nerve stimulation at no trade-off with pacing threshold and lead stability. Quadrupolar leads seem to be associated with a lower incidence of VT/VF and pulmonary congestion, when compared with bipolar leads, but further investigations are necessary to confirm that this positive effect is associated with better LV reverse remodeling.

© 2018 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Cardiac resynchronization therapy (CRT) is an effective treatment in patients with symptomatic heart failure (HF), prolonged QRS duration and impaired left ventricular (LV) systolic function. However, some issues may limit patient response.

Approximately, 30% of patients treated by CRT do not respond in terms of reverse remodeling, and this is associated with worse clinical outcomes. Left-ventricular lead dislodgement from the targeted pacing site, phrenic nerve stimulation, high pacing threshold and suboptimal LV lead position are some of the causes of non-response and altogether these issues may account for failure to provide CRT in up to 15% of patients when unipolar or bipolar LV leads are employed. Quadrupolar LV leads have been developed to enhance the stimulation of targeted sites while minimizing the risk of phrenic nerve stimulation (PNS) and lead dislodgement. Quadrupolar lead designs are different with regard
to inter-electrode spacing among manufacturers. In particular a short inter-electrode spacing between the 2nd and 3rd electrode has been associated with increase in the safety margin between phrenic and LV threshold without affecting the pacing site (Fig. 1). We performed a multicenter observational study to evaluate whether the utilization of the Attain Performa (Medtronic, Dublin, Ireland) quadripolar lead is safe, effective and possibly associated with improved clinical outcomes when compared to bipolar leads.

2. Methods

2.1. Population

We performed a retrospective analysis of all consecutive patients implanted from January 2012 to January 2015 with a Medtronic CRT defibrillator (CRT-D) and a bipolar lead or quadripolar Attain Performa lead according to ESC guidelines by 14 Italian cardiology centers participating in the ClinicalService project.

2.2. Design

Participating centers prospectively collected data of all patients wearing a Medtronic CRT device in the framework of the ClinicalService project [Clinical Trial Registration Information: http://clinicaltrials.gov/ct2/show/NCT01007474], ongoing in Italy since 2004. This is a medical care project that aims at evaluating and improving the use of implantable cardiac devices in the clinical practice of Italian sites. The ClinicalService data repository can be also retrospectively interrogated to test specific physicians' hypotheses.

The project was approved by the Ethics Committee or Medical Director of each participating center and complies with the principles outlined in the Declaration of Helsinki. Each patient provided informed consent for data collection and analysis. Since March 2013, all the quadripolar lead was launched to the market, physicians from the 14 centers participating in this study chose to use quadripolar LV lead as the first choice in all consecutive CRT implants. As control group, all patients implanted with standard bipolar leads and included in the ClinicalService project since January 2012 were selected. Follow-up performance and clinical outcomes were compared between the cohorts of patients with quadripolar and bipolar leads whose complete follow-up data was available.

The rate of quadripolar leads was different between the participating centers, but the distribution of each site was not greater than 20% of the total cohort.

2.3. Objectives

The primary objective of our analyses was to evaluate the performance of Attain Performa quadripolar lead in clinical practice.

The secondary objective was to compare clinical outcomes and follow-up HF status of patients implanted with quadripolar lead vs. patients implanted with standard Medtronic passive fixation bipolar leads in the year before Attain Performa market release.

2.4. Attain performa lead and bipolar lead characteristics

The Attain Performa™ Quadripolar lead features steroid on all four LV pacing electrodes. Inter-electrode spacing is 21 mm between the first and second electrode and between the third and fourth electrode, while it is 13 mm between the second and third electrode. The narrow-spaced electrodes, "Short Bipolar", were designed to reduce the chance of stimulation of the phrenic nerve without compromising pacing capture thresholds.

This lead is intended to be placed into tributaries of the coronary sinus for the provision of CRT. It is available in three shapes: model 4298 is canted with a compound curve at the distal end (Fig. 1a), model 4398 is a straight lead with tines (Fig. 1b) and model 4598 has an offset S-shaped curve at the distal end (Fig. 1c). All three lead models are constructed with an 154 connector and have 5.3 French (Fr) proximal and 3.9 Fr distal lead body diameters.

The control group consisted of standard Medtronic passive fixation bipolar leads of the Attain Bipolar over the wire (OTW) or Attain Ability families. The Attain Bipolar OTW (model 4194) is a 6 Fr steroid eluting true bipolar lead, with an inter-electrode spacing of 11 mm and a canted distal end for passive fixation into the vein. The Attain Ability is a dual cathode steroid eluting lead, with an inter-electrode spacing of 21 mm ad it is available in three models: 4 Fr canted lead (model 4196), 5.3 Fr canted lead (model 4296) and 4 Fr straight tined lead (model 4396).

2.5. Clinical and lead data collection

At baseline (prior to CRT-D implantation), patients of both groups were evaluated according to the clinical practice of each center with the collection of available data regarding clinical history, NYHA functional class, 12-lead electrocardiography (ECG) and echocardiography (ECHO). During the implantation procedure of the quadripolar lead, before taking the coronary venogram, the implanting physician determined a target pacing point for the left-ventricular pacing on the 30° right anterior oblique (RAO) view and on the 45° left anterior oblique (LAO) and identified the target pacing site (TPS) as a 2 cm diameter area around the target pacing point (pre-operative TPS selection). TPS selection was not performed using a standardized image-guided approach in all patients, but each physician decided according to his clinical practice: in some patients the target pacing site was chosen a priori (without additional tests) in a posterolateral area, while in others it was decided after a speckle tracking ECHO or magnetic resonance imaging (MRI).

The coronary sinus (CS) venograms in 40° LAO view and in 30° RAO view were recorded and stored. After the venogram, the implantor determined the presence/absence of a target vein, defined as a suitable cardiac vein leading to the target pacing site. Before leaving the operating room, the left-ventricular pacing threshold (LVPT) and PNS threshold (PNST) of the quadripolar lead were measured and a final pacing vector was chosen from the 16 available. The final LV pacing site was defined as the location of the cathode of the final pacing vector. Device programming of lower rate limit, rate response, atrioventricular (AV) intervals, ventricular tachycardia or fibrillation (VT/VF) detection intervals and cut-off rates was left to physician discretion.

Patient clinical assessment, electrical parameters of the quadripolar lead (LVPT and PNST), and all adverse events were recorded at routine follow-up. Device diagnostic data retrieved
from the device memory at each ambulatory or remote follow-up were stored in the ClinicalService® electronic database.

2.6. Device diagnostics data

Device diagnostics stored information about atrial tachycardia or fibrillation (AT/AF), ventricular rate during AF, fluid volume congestion through intrathoracic impedance measurements (OptVol® fluid index), patient activity, night heart rate, heart rate variability (HRV), the percentage of CRT pacing and detected episodes of VT/VF. A close correlation between changes in some of these individual or combined HF diagnostics data and HF events have been shown in several studies. We also estimated the PARTNERS-HF index as a combined risk of HF worsening.

Diagnostic data from the first month after implantation were excluded from the analysis.

2.7. Statistical analysis

Continuous variables with a normal distribution were expressed as mean and standard deviation, or median and first and third quartiles in the case of skewed distributions. Baseline characteristics as well as diagnostic parameter values were compared between groups by means of the chi-square test, Fisher exact test, Student's t-test or the Wilcoxon-Mann-Whitney test as appropriate. As sensitivity analysis, the two cohorts were propensity matched (see Supplemental Appendix - Table SA1 and SA2). The propensity score was obtained from a logistic model for lead implanted, including age, history of HF and history of atrial arrhythmias. All statistical tests were two-sided and deemed to be statistically significant if \( p < 0.05 \). Analyses were carried out using SAS 9.4 version software (SAS Institute Inc., Cary, NC, USA).

3. Results

Fig. 2 shows the number of patients included in the two analyses of our project. Median follow-up period was 14 months (25–75 percentile: 8–15 months).

3.1. Quadrupolar lead performance at implant and follow-up

3.1.1. Quadrupolar lead implantation details

A total of 215 patients were implanted with the quadripolar lead in the 14 participating centers in Italy. Baseline characteristics of the patients are described in the second column of Table 1.

Concerning the type of procedure, 176 (80%) were first implants; while ipsilateral upgrading was done in 28 (13%) patients and post-extraction re-implantations were done in 16 (7%) patients. A left-sided access was used in 92.5% of the procedures.

In 158 (74%) cases, the implanters used the 4298 model (dual canted), in 29 (12%) the 4398 (straight) and in 28 (13%) the 4598 (S-shaped).

The choice of target pacing site was a lateral or posterolateral area by default, without additional testing, in 157 (73%) patients, while additional evaluations, like speckle tracking 2D echo criteria or assessment of scar area using MRI, were made in 63 (27%) patients. The angiogram was performed in 195 patients (96%). In the other patients, the presence of a vein that matched with the target pacing site was tested by advancing a 0.014 Fr angioplasty guidewire. All the patients had at least one target vein. The target vein was lateral in 98 patients (45.6%), posterolateral in 86 patients (40.0%), anterolateral in 21 patients (9.8%) and posterior in 10 patients (4.6%).

The lead was successfully implanted in the chosen target vein in 196 patients (91%). In the other 19 (9%) patients, the Performa lead was placed in a second-choice vein that was nearby the target pacing site: in 16 (7%) patients it was not possible to insert and advance the lead in the target vein, in 3 (2%) patients the target vein was considered too short for the quadripolar lead (with a high risk of dislodgement).

No quadripolar lead acute dislodgements were reported, while 1 acute procedure-related complication occurred in the bipolar control group. A total of 4 (2%) dislodgements (needing a surgical replacement) occurred during the median observation period of 14 months, while 3 (2.5%) in the bipolar control group.

3.1.2. Quadrupolar lead placement, pacing vectors and pacing sites

Final lead tip and short bipolar locations are reported in Fig. 3. In 20 patients (9.5%) in the final lead location the proximal electrode (LV4) remained outside the target vein. Among them, in 2 patients a late lead dislodgement occurred during the observation period.

In 50% of patients the chosen final pacing configuration at implant would not have been available with a conventional bipolar lead. In particular a short bipolar configuration (LV2-LV3) was programmed in 44 patients (20.4%). The reason for final pacing configuration choice was device longevity for 79% patients, and avoidance of phrenic nerve stimulation for 21% of patients. A dedicated quadripolar pacing vector was chosen more frequently when the IV tip location was apical than otherwise (65.6% vs 42.7%, respectively.

Fig. 2. Patients included in the two analyses.
Table 1
Baseline characteristics of patient population.

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>First Analysis (N = 215)</th>
<th>Second Analysis</th>
<th>p-value A vs B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>all Quadrupolar lead</td>
<td>Quadrupolar with follow-up (N = 109) A</td>
<td>Bipolar with follow-up (N = 121) B</td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at first implant (ys), mean ± SD</td>
<td>68.8 ± 11.0</td>
<td>69.2 ± 10.1</td>
<td>0.608</td>
</tr>
<tr>
<td>Gender (Male), % (n)</td>
<td>76.9% (165)</td>
<td>72.5% (79)</td>
<td>0.134</td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of HF, % (n)</td>
<td>90.6% (195)</td>
<td>90.7% (99)</td>
<td>0.094</td>
</tr>
<tr>
<td>NYHA III / IV, % (n)</td>
<td>61.5% (132)</td>
<td>72.4% (79)</td>
<td>0.087</td>
</tr>
<tr>
<td>VT/VF, % (n)</td>
<td>7.6% (16)</td>
<td>8.5% (9)</td>
<td>0.472</td>
</tr>
<tr>
<td>AF/AT, % (n)</td>
<td>31.6% (68)</td>
<td>29.5% (32)</td>
<td>0.732</td>
</tr>
<tr>
<td>Ischemic Cardiomyopathy, % (n)</td>
<td>42.8% (92)</td>
<td>48.6% (53)</td>
<td>0.813</td>
</tr>
<tr>
<td>1st grade AV block, % (n)</td>
<td>14.5% (32)</td>
<td>17.0% (18)</td>
<td>0.341</td>
</tr>
<tr>
<td>2nd grade AV block, % (n)</td>
<td>3.7% (8)</td>
<td>4.0% (4)</td>
<td>0.479</td>
</tr>
<tr>
<td>3rd grade AV block, % (n)</td>
<td>8.0% (17)</td>
<td>9.0% (10)</td>
<td>0.173</td>
</tr>
<tr>
<td>RBBB, % (n)</td>
<td>6.0% (13)</td>
<td>6.0% (6)</td>
<td>0.226</td>
</tr>
<tr>
<td>LLBB, % (n)</td>
<td>71.6% (154)</td>
<td>68.0% (74)</td>
<td>0.590</td>
</tr>
<tr>
<td>Left Hemi block, % (n)</td>
<td>4.5% (10)</td>
<td>6.1% (7)</td>
<td>0.968</td>
</tr>
<tr>
<td>SND, % (n)</td>
<td>7.8% (17)</td>
<td>7.8% (8)</td>
<td>0.405</td>
</tr>
<tr>
<td>QRS (ms), mean ± SD</td>
<td>152.2 ± 23.9</td>
<td>150.5 ± 22.9</td>
<td>0.918</td>
</tr>
<tr>
<td>History of stroke/TA, % (n)</td>
<td>8.9% (19)</td>
<td>7.5% (8)</td>
<td>0.548</td>
</tr>
<tr>
<td>Valvular surgery, % (n)</td>
<td>11.2% (24)</td>
<td>11.9% (13)</td>
<td>0.482</td>
</tr>
<tr>
<td>Hypertension, % (n)</td>
<td>61.2% (132)</td>
<td>66.3% (72)</td>
<td>0.671</td>
</tr>
<tr>
<td>Diabetes, % (n)</td>
<td>22.3% (48)</td>
<td>23.5% (26)</td>
<td>0.514</td>
</tr>
<tr>
<td>Chronic kidney disease, % (n)</td>
<td>18.0% (39)</td>
<td>20.8% (23)</td>
<td>0.079</td>
</tr>
<tr>
<td>COPD, % (n)</td>
<td>19.5% (43)</td>
<td>23.7% (26)</td>
<td>0.080</td>
</tr>
<tr>
<td>Cardiovascular hospitalization, % (n)</td>
<td>51.8% (1111)</td>
<td>44.2% (48)</td>
<td>0.056</td>
</tr>
<tr>
<td>Echo at baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVFE, % (n), mean ± SD</td>
<td>27.8 ± 6.6</td>
<td>28.0 ± 6.8</td>
<td>0.847</td>
</tr>
<tr>
<td>LVEDV (ml), mean ± SD</td>
<td>209.8 ± 85.7</td>
<td>209.7 ± 76.0</td>
<td>0.903</td>
</tr>
<tr>
<td>LVESV (ml), mean ± SD</td>
<td>153.0 ± 71.2</td>
<td>158.7 ± 69.2</td>
<td>0.803</td>
</tr>
<tr>
<td>Mitral regurgitation, % (n)</td>
<td>91.6% (197)</td>
<td>90.5% (99)</td>
<td>0.646</td>
</tr>
<tr>
<td>Medication at baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>75.8% (163)</td>
<td>75.5% (82)</td>
<td>0.123</td>
</tr>
<tr>
<td>Diuretic</td>
<td>79.5% (171)</td>
<td>81.1% (88)</td>
<td>0.432</td>
</tr>
<tr>
<td>Anti-platelet</td>
<td>47.0% (101)</td>
<td>53.6% (59)</td>
<td>0.451</td>
</tr>
<tr>
<td>OAC</td>
<td>61.7% (137)</td>
<td>60.4% (66)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ACE-Inhibitor/AKB2</td>
<td>54.4% (117)</td>
<td>57.5% (63)</td>
<td>0.348</td>
</tr>
</tbody>
</table>

p = 0.003. During a median follow-up of 14 months, physician changed the pacing configuration at least once in 59 (54.1%) patients. Main reasons for a configuration change were an increased LIVPT (62.5% patients), PNS management (12.5%), or optimization of device programming to improve patient response to CRT (25.0%).

Configuration changes from a standard vector (one available in bipolar leads also) to a specific quadrupolar pacing vector occurred in 17 (15.6%) patients. In 12 (11.0%) patients the reverse change occurred.

Fig. 4 shows LV-stimulation pacing-site locations at implantation and at last available follow-up. These were basal or middle ventricular in 87.5% of the patients after implantation and in 83.5% of patients at last follow-up, despite the tip of the quadriplear lead is apical in 36.2% of patients (Fig. 3A).

3.1.3. Phrenic nerve stimulation and pacing threshold in quadrupolar leads

Phrenic nerve stimulation at 8 V at 0.4 ms with the final pacing vector was observed in 54 patients (25.1%) at implantation and in 21 patients (19.4%) at a median follow-up of 14 months, respectively. At implant median LIVPT was 1 V at 0.4 ms [25–75 percentile: 0.5V–1.3 V] and it was lower than 2.5 V at 0.4 ms in final pacing configuration in 202 patients (94%) with a safety margin between PNST and LIVPT of >3 V in 190 (88%) patients. During the follow-up period, LIVPT was 1 V at 0.4 ms [25–75 percentile: 0.75V–1.5V] (p = 0.132 versus implant) and it was lower than 2.5 V at 0.4 ms in 98 patients (90%) with a safety margin between phrenic nerve threshold and LV of >3 V in
97 (89%) patients. In Table 2a and b, we report the percentage of patients with pacing capture threshold of no greater than 2.5 V, according to final pacing configuration, associated with the absence of PNS or a safety margin greater than 3 V in our population, at implant and follow-up.

Both standard vectors, already available in standard bipolar lead, and new vectors specific for the quadripolar lead have been programmed and resulted in a mean LVPT lower than 1.5 V at 0.4 ms and in a guaranteed safety margin between pacing and PNS thresholds of at least 3 V in more than 86% of patients, both at implant and at follow-up.

3.2. Comparison between quadripolar and bipolar leads

At long term follow-up 109 patients of the quadripolar group had a clinical follow-up. Among them, 97 had a complete device diagnostics dataset available. We compared these patients with a control group of 121 patients (116 with complete device data collection) with standard bipolar leads. Baseline characteristics of the two patient populations are reported in third and fourth columns of Table 1. There were no statistical differences between the two groups, even if quadripolar group seems to have more patients with chronic kidney diseases, chronic pulmonary obstructive disease (COPD) and pre-implant cardiovascular hospitalizations.

Median follow-up length was 14 months for both groups. No significant differences were observed at follow-up between quadripolar and bipolar group in term of mean LVPT (1.19 ± 0.85 vs. 1.44 ± 1.22 V at 0.4 ms, respectively), percentage of patients with high LVPT (9.7% vs. 13.3%, with LVPT > 2.5 V at 0.4 ms respectively) and number of patients with PNS requiring surgical intervention (0% vs. 0.8%, respectively). The incidence of clinical and device-derived outcomes is shown in Table 3.

The quadripolar lead group had a lower percentage of patients (27%) with at least 1 day with an OptiVol fluid index higher than 100 in comparison to the bipolar group (44%, p = 0.015). Ventricular arrhythmias were detected by the device in a lower percentage of patients of the quadripolar lead group (9%) compared with bipolar lead group (22%, p = 0.015). The other device-derived outcomes did not show significant differences. Patients with at least 1 day with PARTNERS-HF worsening HF risk were 65 (67.6%) in the quadripolar lead group and 90 (77.6%) in the bipolar lead group (p = 0.084).

Analysis on the propensity-matched cohorts confirmed results on the whole population.

4. Discussion

Several factors contribute to either reverse LV remodeling or clinical improvement following CRT delivery. Non-optimal LV

Table 2

<table>
<thead>
<tr>
<th>Final Pacing Configuration</th>
<th>n</th>
<th>Mean LVPT (V @ 0.4 ms)</th>
<th>LVPT ≤ 2.5 Vspts</th>
<th>LVPT ≤ 2.5 V and No PNSpts</th>
<th>LVPT ≤ 2.5 V and PNST-LVPT &gt; 3 Vspts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vector available in Bipolar lead</td>
<td>107</td>
<td>1.15 ± 0.74</td>
<td>93.5%</td>
<td>86.7%</td>
<td>87.1%</td>
</tr>
<tr>
<td>Vector NOT available in Bipolar lead</td>
<td>108</td>
<td>1.10 ± 0.68</td>
<td>94.6%</td>
<td>88.5%</td>
<td>89.1%</td>
</tr>
<tr>
<td>Short Bipole</td>
<td>44</td>
<td>0.83 ± 0.35</td>
<td>97.4%</td>
<td>79.5%</td>
<td>89.7%</td>
</tr>
</tbody>
</table>

b. Last follow-up.

LVPT and PNS by final configuration

<table>
<thead>
<tr>
<th>Final Pacing Configuration</th>
<th>n</th>
<th>Mean LVPT (V @ 0.4 ms)</th>
<th>LVPT ≤ 2.5 Vspts</th>
<th>LVPT ≤ 2.5 V and No PNSpts</th>
<th>LVPT ≤ 2.5 V and PNST-LVPT &gt; 3 Vspts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vector available in Bipolar lead</td>
<td>47</td>
<td>1.10 ± 0.67</td>
<td>93.6%</td>
<td>86.4%</td>
<td>86.4%</td>
</tr>
<tr>
<td>Vector NOT available in Bipolar lead</td>
<td>62</td>
<td>1.35 ± 0.65</td>
<td>86.7%</td>
<td>80.0%</td>
<td>86.7%</td>
</tr>
<tr>
<td>Short Bipole</td>
<td>19</td>
<td>1.09 ± 0.76</td>
<td>86.7%</td>
<td>80.0%</td>
<td>86.7%</td>
</tr>
</tbody>
</table>

PNST: phrenic nerve stimulation threshold; LVPT: left-ventricular pacing threshold.

*p-values > 0.01 for comparison vs Vector available in Bipolar lead.
Table 3
Patients experiencing clinical and device diagnostics outcomes.

<table>
<thead>
<tr>
<th></th>
<th>Quadrupolar (N = 97)</th>
<th>Bipolar (N = 116)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death for any cause</td>
<td>Patients, n (%)</td>
<td>3 (3.7%)</td>
<td>3 (2.5%)</td>
</tr>
<tr>
<td>Cardiogenic or device-related hospitalization</td>
<td>Patients, n (%)</td>
<td>6 (5.5%)</td>
<td>7 (5.8%)</td>
</tr>
<tr>
<td>VT/VF detected episodes</td>
<td>Patients, n (%)</td>
<td>9 (9.2%)</td>
<td>25 (21.6%)</td>
</tr>
<tr>
<td>Thoracic fluid level over threshold</td>
<td>Patients, n (%)</td>
<td>27 (27.5%)</td>
<td>51 (44.0%)</td>
</tr>
<tr>
<td>Optovol fluid index &gt; 100 Ω</td>
<td>Patients, n (%)</td>
<td>10 (10.3%)</td>
<td>12 (10.3%)</td>
</tr>
<tr>
<td>New onset of AT/AF (&gt;6 h spent in AF on at least 1 day)</td>
<td>Patients, n (%)</td>
<td>30 (32.9%)</td>
<td>38 (34.8%)</td>
</tr>
<tr>
<td>High Ventricular rate during AF (daily average ventricular rate occurring during AF on a specific day &gt;90 beats/min)</td>
<td>Patients, n (%)</td>
<td>63 (66.9%)</td>
<td>73 (62.5%)</td>
</tr>
<tr>
<td>Low Patient activity (daily average patient activity &lt;1 h on at least 1 day)</td>
<td>Patients, n (%)</td>
<td>42 (43.3%)</td>
<td>50 (43.1%)</td>
</tr>
<tr>
<td>High Night heart rate (average ventricular rate from 12AM to 4AM &gt;85 beats/min on at least 1 day)</td>
<td>Patients, n (%)</td>
<td>46 (48.6%)</td>
<td>60 (57.9%)</td>
</tr>
<tr>
<td>CRT pacing percentage &lt;90% on at least 1 day</td>
<td>Patients, n (%)</td>
<td>50 (52.6%)</td>
<td>56 (50.0%)</td>
</tr>
<tr>
<td>Days/patients, Median (Q1-Q3)</td>
<td>Patients, n (%)</td>
<td>49 (4-193)</td>
<td>25 (4-140)</td>
</tr>
<tr>
<td>Risk of worsening HF (PARTNER HF) (at least once between fluid index &gt;100 Ω days or any 2 of the other criteria listed in this table)</td>
<td>Patients, n (%)</td>
<td>65 (67.0%)</td>
<td>90 (77.6%)</td>
</tr>
</tbody>
</table>

*a New onset of AT/AF was defined as no AT/AF episodes reported at baseline visit (in case of first implantation) or in the device memory (in case of device replacement). New onset with more than 6 h of AT/AF a day was considered as an impaired patient clinical condition. 
** First month after implantation has been excluded from this analysis, to exclude the time of implant hospitalization.

Pacing site induced by complex coronary sinus vein anatomy, phrenic nerve stimulation and high pacing threshold may cause CRT non-response.2-4

New leads and access tools for LV pacing from cardiac veins have enhanced lead placement into a targeted area improving the success of CRT implantation.4

4.1. Main results

Quadrupolar leads were associated with 1) high electrical performance, 2) low dislodgement rates, 3) no PNS issues and 4) favorable comparison with bipolar leads in terms of incidence of pulmonary congestion or VT/VF occurrence.

4.2. Electrical performance

Our data show that Attain Performa quadrupolar leads have excellent acute and chronic electrical performance confirming previous data; noteworthy 16 patients (7%) with a previous lead extraction needing a right sided re-implantation were included in our cohort. The lack of vessels, the stenosis or thrombosis or narrowing of coronary sinus branches post-extraction did not seem to affect the procedural outcome of quadrupolar implant considering our successful experience in the reimplantation setting; a result that favorably compares with previously published experiences with bipolar LV pacing leads13 and with other quadrupolar leads.2,4

4.3. Dislodgements

A second challenge in cardiac resynchronization is to prevent LV lead dislodgement. Till date a dislodgement rate of 9-10% has been reported with the use of bipolar leads. Multipolar leads enable the tip to be wedged in the distal part of the vein (improving lead stability) and then to pace at mid and basal sites (this is considered superior to apical pacing).14 In our cohort of quadrupolar leads, it was confirmed that only 12.5% of patients were paced apically (Fig. 4a), despite the tip of the quadrupolar lead was apical in 36.2% of the patients (Fig. 3a). The dislodgement rate with the St. Jude’s Quartet quadrupolar lead has been reported to be around 3.5% at 3 months.15 The rate of dislodgement requiring repeated surgery was 1% in the Attain Performa quadrupolar lead family at 6-months follow-up,6 which is significantly better compared with the bipolar leads3 and Quartet quadrupolar leads.7,16 Our data also confirms a low dislodgement rate (2%) at 14 months. It is noteworthy to mention that, while minor dislodgements are treated with cathode reprogramming, the true lead stability may be underestimated and only dislodgements requiring repeated surgery are reported in the literature.

4.4. Phrenic nerve stimulation

PNS poses significant limitations to LV stimulation, as reported.4,17 In our analysis we showed that, although PNS detection was comparable to literature values, the Attain Performa lead warranted a safety margin greater than 3 V between PNS threshold and LVPT in 88% of patients at implant and 83% at follow-up, which was observed to be advantageous for patients with PNS at implantation.16 Indeed, a short pacing dipole increases the PNS threshold without affecting the LV threshold.5,8,18 20% of our patients were paced by the short-spaced configurations, and 50% of patients with a pacing configuration not available with a bipolar lead. Pacing vectors available in a quadrupolar lead were programmed more often when the LV lead tip was in the distal part of the vein to achieve a more proximal stimulation site. A high pacing threshold is frequently associated to PNS management with bipolar LV leads.19 Because of a high LV threshold when using LV3 and LV4 as cathode, more than 75% of patients with a Quartet lead resulted in a pacing vector available with conventional bipolar leads.7 In contrast, in our population as well as in Crossey’s study,5 more than 40% of patients were programmed with a pacing vector available with a quadrupolar lead only, with LVPT comparable to those of standard bipolar leads and no cases of surgical re-intervention needed to solve PNS. Moreover, several pacing vectors were suitable for LV stimulation below battery voltage, which prolongs device longevity.

4.5. Clinical outcomes

Data on the effect of the quadrupolar leads in term of response to the CRT are scarce.18 Our research compared the outcome of patients implanted with quadrupolar leads vs bipolar leads in terms of survival, cardiovascular or device-related hospitalizations, VT/VF occurrence and device-based indexes of worsening HF. We observed a lower incidence of VT/VF and pulmonary congestion in quadrupolar leads as compared with bipolar leads. These findings may represent a signal that the use of quadrupolar leads improves the possibility to achieve LV reverse remodeling but of course this hypothesis would warrant a solid confirmation in randomized controlled studies. Indeed, it is known that reverse remodeling is
associated with lower occurrence of VT/VF.20 Behar et al reported an advantage in terms of mortality and PNS management with quadrupolar leads compared to bipolar LV leads.21 Their findings have to be evaluated taking into account that ischemic heart disease and AF were significantly more common in the bipolar leads group and that the LV lead dislodgement and redo surgery rate in the bipolar group could have been associated with a learning curve effect by some centers, later resolved in the quadrupolar lead series.

4.6. Limitations

The limitations of multicenter observational studies and retrospective analyses, including factors such as potential bias in patient selection, patient treatment and device programming, apply to our research. Nevertheless, possible biases are mitigated by the fact that data were collected prospectively, the analysis plan and research objectives were designed before opening the dataset and the analysis on the propensity matched cohorts confirmed results obtained in the whole population. Some data, such as echo data or PNS information, were not available for the whole population. The number of patients included in the study is small; however, the inclusion of all-comers, for example also post-extraction patients, allowed us to evaluate quadrupolar leads in real clinical practice conditions.

Due to lack of randomization and the use of an historical control group, no evaluation of patient drop-out rate during the training because of PNS or lead instability is available, and no comparison of success implant rate or time to LV lead placement and procedural data can be made. In addition, due to the growing use of remote monitoring system for patient follow-up, about 50% of patients did not perform an in-office visit with complete data collection.

5. Conclusion

Our data show that Attain Performa quadrupolar leads enable implanters to reach a targeted lead positioning even in challenging cases. These short-spaced quadrupolar leads improve the management of PNS at no trade-off with pacing threshold and lead stability, which eventually become “minor” problems for CRT provision. In addition, quadrupolar leads may be associated with a lower incidence of VT/VF and pulmonary congestion when compared with bipolar leads. However, further investigation through randomized controlled studies is necessary to assess whether this positive quadrupolar lead effect is associated with better LV reverse remodeling.

Conflict of interest

M.Z. received speaker’s fees from Medtronic and Boston Scientific; G.B. received speaker’s fees from Boston Scientific, Medtronic, St. Jude and Boehringer Ingelheim; M.B. received speaker’s fees from Medtronic and Biotronik; D.R. received speaker’s fees from Boehringer Ingelheim; G.Z. is a Medtronic Consultant without relevant financial relationship; M.G.B. received speaker’s fees from Boston Scientific, Medtronic, Biosense Webster, Spectranetics.

Acknowledgements

The authors wish to thank Annamaria Varbaro, Jennifer Comisso and Lorenza Mangoni for their technical and scientific support.

Appendix A. Participating center list

M. Ziacci, M. Biffi, G. Boriani, I. Diemberger, C. Martignani, A. Corzani, G. Massaro, A. Mazzotti – Azienda ospedaliera universitaria S. Orsola – Malpighi, Bologna
G. Zucchielli, S. Viani, MG Bongiorni – Azienda ospedaliera universitaria pisana, Pisa
D. Ricciardi, V. Calabrese – Policlinico universitario Campus Biomedico, Roma
G. Morani, L. Tomasi – Azienda ospedaliera universitaria di Verona, Verona
E. De Ruvo, A. Fagagnini, L. Calò – Policlinico Casilino, Roma
Calzolari, L. De Mattia, M. Crosato – Azienda ULSS9 ospedale Cà Foscari, Treviso
E. Pisanò, G. Milanese – Ospedale Vito Fazzi, Lecco
P. Di Filippo, P. Ferrari – Azienda ospedaliera Papa Giovanni XXIII, Bergamo
S. Favale, G. Luzzi – Azienda ospedaliera universitaria Policlinico di Bari
R. Melloni – Azienda ospedaliera Fatebenefratelli e oalmático, Milano
F. Quartieri – Arcispedale Santa Maria Nuova, Reggio Emilia
M. Accogli, P. Palmisano – Azienda ospedaliera Cardinal Panico, Tricase
G. Rovaris, E. Piazzì – Azienda ospedaliera S. Gerardo, Monza
G. Senatore, C. Amellone – A.S.L. TO4 Ospedale Civile, Cirie

Appendix B. Supplementary data

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.ijhe.2018.05.007.

References


